Interleukin-2 improves tumour response to DNP-modified autologous vaccine for the treatment of metastatic malignant melanoma

This paper is a report of response rate (RR) and survival of 34 metastatic melanoma patients who received a dinitrophenyl (DNP)-modified autologous melanoma cell vaccine. In all, 27 patients started the vaccine as a primary treatment for metastatic melanoma and seven started it as an adjuvant, with...

Descripción completa

Detalles Bibliográficos
Autores principales: Lotem, M, Shiloni, E, Pappo, I, Drize, O, Hamburger, T, Weitzen, R, Isacson, R, Kaduri, L, Merims, S, Frankenburg, S, Peretz, T
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2004
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2410164/
https://www.ncbi.nlm.nih.gov/pubmed/14970852
http://dx.doi.org/10.1038/sj.bjc.6601563

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2410164/
https://www.ncbi.nlm.nih.gov/pubmed/14970852
http://dx.doi.org/10.1038/sj.bjc.6601563

Ejemplares similares